Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838874 | 1.00 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL30545232 | 1.00 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL2394195 | 0.84 | MEN1 (1.00) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL29369964 | 0.84 | MEN1 (1.00) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL2394204 | 0.84 | MEN1 (1.00) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL1430608 | 0.83 | MEN1 (0.73) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL794085 | 0.83 | MEN1 (0.73) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL29580190 | 0.83 | MEN1 (0.98) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL8923309 | 0.81 | MEN1 (0.65) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL8923310 | 0.81 | MEN1 (0.65) | MEN1ALOX15CYP2C19KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5668121-A | Glutamate (NMDA) receptor antagonists | WARNER-LAMBERT COMPANY (US) | 1997-09-16 | — | — | US | claimed |
| US-20260060932-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA LP (US) | 2026-03-05 | — | — | US | disclosed |
| US-20240238207-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA LP (US) | 2024-07-18 | — | — | US | disclosed |
| US-11911512-B2 | Encased tamper resistant controlled release dosage forms | PURDUE PHARMA L.P. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230301921-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA L.P. | 2023-09-28 | — | — | US | disclosed |
| CN-104873455-B | Coated Tamper Resistant Controlled Release Dosage Forms | 普渡制药公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11590082-B2 | Encased tamper resistant controlled release dosage forms | PURDUE PHARMA L.P. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210251907-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA L.P. | 2021-08-19 | — | — | US | disclosed |
| US-10966932-B2 | Encased tamper resistant controlled release dosage forms | PURDUE PHARMA L.P. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200121608-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA LP (US) | 2020-04-23 | — | — | US | disclosed |
| CN-1407884-A | Controlled release hydrocodone formulations | EURO CELTIQUE SA (LU) | 2003-04-02 | — | — | CN | disclosed |
| US-20020192277-A1 | Controlled release hydrocodone formulations | PURDUE PHARMA L.P. | 2002-12-19 | — | — | US | disclosed |
| EP-1227798-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | Euro-Celtique S.A. (LU) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002036099-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | EURO-CELTIQUE S.A. (LU) | 2002-05-10 | — | — | WO | disclosed |
| WO-2000018378-A9 | SUSTAINED RELEASE HYDROMORPHONE FORMULATIONS EXHIBITING BIMODAL CHARACTERISTICS | EURO CELTIQUE SA (LU) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001032148-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000018378-A1 | SUSTAINED RELEASE HYDROMORPHONE FORMULATIONS EXHIBITING BIMODAL CHARACTERISTICS | EURO-CELTIQUE, S.A. (LU) | 2000-04-06 | — | — | WO | disclosed |
| US-5695751-A | ADMINISTERING L-AMINO ACID OXIDASE TO REDUCE PLASMA LEVEL OF LARGE AMINO ACIDS TO ALLOW INCREASED TRANSPORT OF LARGE AMINO ACID DRUGS ACROSS BLOOD BRAIN BARRIER | CORNELL RESEARCH FOUNDATION, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5668121-A | Glutamate (NMDA) receptor antagonists | WARNER-LAMBERT COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5489717-A | Glutamate (NMDA) receptor antagonists | WARNER-LAMBERT COMPANY | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060932-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | OGFR, OPRM1, OPRK1 | MEN1 4797/4885ALOX15 2353/4885CYP2C19 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.